Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants
Flores, J.; Perez-Schael, I.; Gonzalez, M.; Garcia, D.; Perez, M.; Daoud, N.; Cunto, W.; Chanock, R.M.; Kapikian, A.Z.
Lancet 1(8538): 882-884
1987
ISSN/ISBN: 0140-6736 PMID: 2882289 Document Number: 296891
The efficacy of the rhesus rotavirus vaccine candidate MMU-18006 was evaluated in a longitudinal double-blind field trial in Caracas, Venezuela. 247 Infants aged 1-10 months were studied and followed for up to 1 year (201 completed the 1-year surveillance): 123 received a dose of 104 plaque-forming units of the vaccine orally and 124 received placebo. 21 Episodes of rotavirus diarrhoea were detected, 16 in the controls and 5 in the vaccinees: vaccine efficacy against any rotavirus diarrhoea was thus 68%. In the 1-5-month-old group the vaccine efficacy was 93%; only 1 episode of rotavirus diarrhoea was detected in 68 vaccines and 15 such illnesses were observed in 65 controls (p < 0.0001). For the entire study group vaccine efficacy was 100% against the most severe rotavirus diarrhoeal episodes.